What records are connected here?
- Evidence lanes
- 3
- Source years
- 10
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2,3Evidence: Large human trials
Peginesatide is a synthetic, peptide-based drug that stimulates red blood cell production. FDA approved it as Omontys in 2012 for anemia from chronic kidney disease in adults on dialysis.2,4 In February 2013 its makers recalled all lots after reports of serious allergic reactions, including fatal anaphylaxis, and FDA withdrew the approval on February 13, 2019, at the company’s request.2 Large randomized trials found it as effective as older drugs at keeping hemoglobin up in people on dialysis, but cardiovascular events and deaths were higher with it in people not on dialysis.4,5
| What it is | A pegylated synthetic peptide that acts as an erythropoiesis-stimulating agent, recorded by FDA’s substance registry as peginesatide and its acetate.1,4 |
|---|---|
| FDA status | Not FDA-approved. FDA approved Omontys on March 27, 2012, and withdrew that approval as of February 13, 2019, after the company asked it to.2 |
| Human evidence | Four randomized, open-label phase 3 trials: two in 1,608 people on hemodialysis and two in 983 people with chronic kidney disease not on dialysis.4,5 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Peginesatide is a synthetic peptide-based erythropoiesis-stimulating agent, a drug that prompts the body to make red blood cells. FDA’s substance registry records it as peginesatide and peginesatide acetate.1,4
In the United States it was the active ingredient of Omontys, NDA 202799, according to Drugs@FDA.3
Like epoetin and darbepoetin, it is an erythropoiesis-stimulating agent used to raise and maintain hemoglobin in people with anemia from advanced chronic kidney disease, according to the trial reports.4,5
In EMERALD 1 and 2, 1,608 people on hemodialysis received peginesatide or continued on epoetin for 52 weeks or more. Peginesatide was noninferior at maintaining hemoglobin, and cardiovascular safety was similar in a pooled analysis of the four trials.4
In PEARL 1 and 2, among 983 people with chronic kidney disease not on dialysis, it matched darbepoetin on hemoglobin, but cardiovascular events and deaths were higher with peginesatide.5
After approval, a dialysis organization that gave it to 19,540 patients reported anaphylaxis and low blood pressure at about 1.4 events per 1,000 patients, including five deaths, according to a 2014 letter.6
Evidence-strength label: Large randomized human trials. How this label is assigned
No. FDA approved Omontys, NDA 202799, on March 27, 2012, for anemia due to chronic kidney disease in adults on dialysis. On February 23, 2013, the makers voluntarily recalled all lots and suspended marketing after postmarketing reports of serious hypersensitivity reactions, including anaphylaxis, which can be fatal.2
At the company’s request, FDA’s approval of NDA 202799 was withdrawn as of February 13, 2019, according to FDA’s Federal Register notice.2
Drugs@FDA still lists Omontys products, as discontinued.3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list peginesatide.7
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Peginesatide is not among them.8,9
Why serious allergic reactions appeared mainly after approval: the 2014 letter notes that the registration trials had shown no such signal.6
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Peginesatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Peginesatide are a bounded selection, not every registration or paper about Peginesatide. For the years before Peginesatide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Peginesatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Peginesatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall. Large randomized trials found it matched older drugs on hemoglobin, with more cardiovascular events in people not on dialysis. Peginesatide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall. Large randomized trials found it matched older drugs on hemoglobin, with more cardiovascular events in people not on dialysis. Peginesatide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Peginesatide acetate, axitinib, and pertuzumab.↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Federal Register notice 2019-02146↗Source date February 13, 2019Regulatory · added November 17, 2026
Federal Register notice 2014-11523↗Source date May 20, 2014Regulatory · added November 17, 2026
Drugs@FDA application NDA202799↗Source date March 27, 2012PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
14 of 14 selected trial records include at least one phase value; 14 of 14 include a status value in the retained structured contract.
16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.
The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
16 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span October 24, 2011 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22683926 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2012-06-11 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23243269 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-12-14 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24023516 in International journal of nanomedicine as Journal Article, Review, with publication-date metadata of 2013-08-26 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24584613 in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-03-01 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22592927 in Analytical and bioanalytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, Validation Study, with publication-date metadata of 2012-05-17 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide.↗
Regulatory
The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.↗
Literature metadata
PubMed lists PMID 23594010 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23594011 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Federal Register · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
The New England Journal of Medicine · Official source · Source checked November 16, 2026
The New England Journal of Medicine · Official source · Source checked November 16, 2026
The New England Journal of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026